147 related articles for article (PubMed ID: 22665914)
1. Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.
Sato K; Uchiyama M
BMJ Case Rep; 2012 Jan; 2012():. PubMed ID: 22665914
[No Abstract] [Full Text] [Related]
2. [Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].
Okamoto S; Tanaka M; Goto T; Nakashima M; Nagura E
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2109-2112. PubMed ID: 29361628
[TBL] [Abstract][Full Text] [Related]
3. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
4. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
5. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Zhang J; Chen B; Xu X
Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
[TBL] [Abstract][Full Text] [Related]
6. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
7. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
8. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
[TBL] [Abstract][Full Text] [Related]
11. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
13. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
[TBL] [Abstract][Full Text] [Related]
14. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
Cheah CY; Seymour JF
Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
[No Abstract] [Full Text] [Related]
15. Richter's syndrome of the brain and the spinal cord.
Graves TD; Collins GP; Parry A
J Neurol Neurosurg Psychiatry; 2011 Aug; 82(8):943-4. PubMed ID: 20587487
[No Abstract] [Full Text] [Related]
16. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
Kansara R; Villa D; Gerrie AS; Klasa R; Shenkier T; Scott DW; Slack GW; Gascoyne RD; Connors JM; Sehn LH; Savage KJ
Br J Haematol; 2017 Nov; 179(3):508-510. PubMed ID: 27443424
[No Abstract] [Full Text] [Related]
17. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
18. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
[No Abstract] [Full Text] [Related]
19. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
Ghose A; Kundu R; Latif T
Crit Rev Oncol Hematol; 2014 Sep; 91(3):292-303. PubMed ID: 24698003
[TBL] [Abstract][Full Text] [Related]
20. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]